Pfizer under pressure after halting drug
(AP)


<p><a href="http://us.rd.yahoo.com/dailynews/rss/health/*http://news.yahoo.com/s/ap/20061204/ap_on_he_me/pfizer_cholesterol_drug"><img src="http://d.yimg.com/us.yimg.com/p/ap/20061203/capt.afe7fcfa4c2544a5bfcd5f7080917817.pfizer_cholesterol_drug_ny117.jpg?x=130&y=87&sig=2IWEMZqhc7IRjVhrB.ofDQ--" align="left" height="87" width="130" alt="Jeff Kindler, CEO of Pfizer, speaks at the opening of their R&D Analyst meeting presentations in Groton Conn., in this Thursday, Nov. 30, 2006 file photo. Pfizer Inc. will likely slash staff and accelerate merger and licensing deals as the pressure on it to improve its financial performance intensified after the weekend's announcement that the company ended development of a key drug, analysts said. (AP Photo/Fred Beckham)" border="0" /></a>AP - Pfizer Inc. will likely slash staff and accelerate merger and licensing deals as the pressure on it to improve its financial performance intensified after the weekend's announcement that the company ended development of a key drug, analysts said.</p><br clear="all"/>